New 治療 `増加するs chance of 生き残り´ for prostate 癌 患者s
患者s with 前進するd prostate 癌 have a greater chance of 生き残り if 扱う／治療するd with a 的d 癌 麻薬 in 新規加入 to chemotherapy, によれば a new 熟考する／考慮する.
分析 of the 熟考する／考慮する 基金d by 癌 研究 UK and AstraZeneca UK 設立する that 追加するing the 麻薬 capivasertib to chemotherapy can 改善する 生き残り 率s for men whose 癌 had spread to other parts of the 団体／死体.
A total of 150 people took part in the 裁判，公判, published in the 定期刊行物 European Urology, run by the Southampton 臨床の 裁判，公判s 部隊 (SCTU) which is based at the University of Southampton’s Centre for 癌 Immunology.
A SCTU spokeswoman said: “Often these 患者s will be given hormone therapy which can help 支配（する）／統制する the 癌’s spread.
“But some 患者s do not 答える／応じる to this 治療 or become 抵抗力のある over time, meaning the 癌 will 進歩 and 患者s will then need chemotherapy.
“Capivasertib is a 的d 癌 麻薬 that stops the signals 癌 独房s use to grow and divide and 研究員s therefore 手配中の，お尋ね者 to see whether 追加するing this 麻薬 to 基準 chemotherapy 治療 could help to 支配（する）／統制する the 癌 for longer and 改善する 結果s for these 患者s.
“The results showed that although capivasertib did not 増加する the time before the 癌 started to grow again (progression 解放する／自由な 生き残り) 全体にわたる 生き残り was 増加するd for 患者s in the capivasertib group compared to those in the placebo group.”
Dr Simon Crabb, associate professor of 医療の oncology, said: “This 裁判，公判 has shown that 追加するing the 麻薬 capivasertib to chemotherapy can 改善する 結果s for 患者s with 前進するd prostate 癌 and may be of particular 利益 for 患者s 以前 扱う／治療するd with hormone therapy.
“Larger 熟考する／考慮するs are now needed to 確認する the findings from the ProCaid 裁判，公判 and 増加する our understanding of how best to use this approach.”
